Gorny Miroslaw K, Williams Constance, Volsky Barbara, Revesz Kathy, Wang Xiao-Hong, Burda Sherri, Kimura Tetsuya, Konings Frank A J, Nádas Arthur, Anyangwe Christopher A, Nyambi Phillipe, Krachmarov Chavdar, Pinter Abraham, Zolla-Pazner Susan
Department of Pathology, New York University School of Medicine, New York, New York 10016, USA.
J Virol. 2006 Jul;80(14):6865-72. doi: 10.1128/JVI.02202-05.
The majority of global human immunodeficiency virus infections are caused by viruses characterized by a GPGQ motif at the tip of the V3 loop. Characterization of anti-V3 monoclonal antibodies (MAbs) that neutralize isolates with the GPGQ V3 motif is an important step in designing vaccines that will induce such Abs. Consequently, seven human anti-V3 MAbs derived from the cells of individuals infected with non-B-subtype viruses (anti-V3(non-B) MAbs) were generated from the cells of individuals from Africa infected with circulating recombinant forms CRF02_AG, CRF09_cpx, and CRF13_cpx, each of which contains a subtype A env gene. Sequence analysis of plasma viruses revealed a GPGQ motif at the apex of the V3 loop from six of the seven subjects and a GPGR motif from one subject. The MAbs were selected with fusion proteins (FP) containing V3(92UG037.8) or V3(JR-CSF) from subtype A or B, respectively. In virus binding assays, five of the seven (71%) anti-V3(non-B) MAbs bound to V3-FPs from both subtype A and subtype B, while only four of the nine (44%) anti-V3(B) MAbs recognized both V3-FPs. Using two neutralization assays, both the anti-V3(non-B) and the anti-V3(B) MAbs neutralized subtype B viruses with similar activities, while the anti-V3(non-B) MAbs exhibited a tendency toward both increased potency and breadth of neutralization against non-B viruses compared to anti-V3(B) MAbs. Statistical significance was not achieved, due in large measure to the sizes of the MAb panels, but the overall pattern of data strongly suggests that viruses with the GPGQ motif at the tip of the V3 loop induce anti-V3 Abs with broader cross-neutralizing activity than do viruses with the GPGR motif.
全球大多数人类免疫缺陷病毒感染是由V3环顶端具有GPGQ基序特征的病毒引起的。鉴定能够中和具有GPGQ V3基序分离株的抗V3单克隆抗体(MAb)是设计能诱导此类抗体的疫苗的重要一步。因此,从感染了循环重组形式CRF02_AG、CRF09_cpx和CRF13_cpx的非洲个体细胞中产生了七种源自感染非B亚型病毒个体细胞的人抗V3 MAb(抗V3(non-B) MAb),每种循环重组形式都包含一个A亚型env基因。血浆病毒的序列分析显示,七名受试者中有六名的V3环顶端存在GPGQ基序,一名受试者存在GPGR基序。这些MAb分别用含有A亚型或B亚型的V3(92UG037.8)或V3(JR-CSF)的融合蛋白(FP)筛选。在病毒结合试验中,七种抗V3(non-B) MAb中有五种(71%)与A亚型和B亚型的V3-FP结合,而九种抗V3(B) MAb中只有四种(44%)能识别两种V3-FP。使用两种中和试验,抗V3(non-B) MAb和抗V3(B) MAb对B亚型病毒的中和活性相似,而与抗V3(B) MAb相比,抗V3(non-B) MAb对非B病毒的中和效力和广度有增加的趋势。由于MAb组的规模,未达到统计学显著性,但数据的总体模式强烈表明,V3环顶端具有GPGQ基序的病毒比具有GPGR基序的病毒诱导的抗V3抗体具有更广泛的交叉中和活性。